HPM Partners LLC reduced its holdings in Acadia Healthcare (NASDAQ:ACHC) by 55.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,193 shares of the company’s stock after selling 20,275 shares during the quarter. HPM Partners LLC’s holdings in Acadia Healthcare were worth $528,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of ACHC. Freshford Capital Management LLC acquired a new stake in shares of Acadia Healthcare in the 4th quarter valued at approximately $31,835,000. Frontier Capital Management Co. LLC lifted its holdings in shares of Acadia Healthcare by 13.2% in the 4th quarter. Frontier Capital Management Co. LLC now owns 2,903,403 shares of the company’s stock valued at $94,738,000 after buying an additional 337,961 shares during the period. Aristotle Capital Management LLC lifted its holdings in shares of Acadia Healthcare by 5.0% in the 4th quarter. Aristotle Capital Management LLC now owns 6,183,866 shares of the company’s stock valued at $201,780,000 after buying an additional 297,069 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Acadia Healthcare by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,662,663 shares of the company’s stock valued at $79,408,000 after buying an additional 176,020 shares during the period. Finally, Royce & Associates LP lifted its holdings in shares of Acadia Healthcare by 169.2% in the 4th quarter. Royce & Associates LP now owns 258,526 shares of the company’s stock valued at $8,436,000 after buying an additional 162,500 shares during the period.
ACHC has been the subject of several recent analyst reports. Wells Fargo initiated coverage on Acadia Healthcare in a report on Tuesday, January 30th. They issued an “outperform” rating and a $41.00 price target for the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $45.00 price objective (up from $40.00) on shares of Acadia Healthcare in a report on Friday, February 23rd. Robert W. Baird reaffirmed a “hold” rating and set a $37.00 price objective on shares of Acadia Healthcare in a report on Friday, December 15th. Credit Suisse Group reaffirmed a “neutral” rating and set a $40.00 price objective (up from $35.00) on shares of Acadia Healthcare in a report on Thursday, February 22nd. Finally, BidaskClub raised Acadia Healthcare from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Acadia Healthcare has a consensus rating of “Buy” and a consensus price target of $44.50.
Acadia Healthcare stock opened at $39.46 on Friday. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 1.25. The firm has a market cap of $3,530.92, a price-to-earnings ratio of 17.16, a P/E/G ratio of 1.30 and a beta of 0.63. Acadia Healthcare has a fifty-two week low of $26.92 and a fifty-two week high of $54.34.
Acadia Healthcare (NASDAQ:ACHC) last released its quarterly earnings results on Wednesday, February 21st. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.07. The company had revenue of $724.50 million during the quarter, compared to the consensus estimate of $713.20 million. Acadia Healthcare had a return on equity of 8.16% and a net margin of 6.92%. Acadia Healthcare’s revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 earnings per share. research analysts anticipate that Acadia Healthcare will post 2.45 EPS for the current year.
In other Acadia Healthcare news, Director Reeve B. Waud sold 7,698 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $42.03, for a total transaction of $323,546.94. Following the completion of the transaction, the director now owns 10,088 shares of the company’s stock, valued at $423,998.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Reeve B. Waud sold 200,000 shares of the firm’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $39.02, for a total value of $7,804,000.00. Following the transaction, the director now directly owns 10,088 shares of the company’s stock, valued at approximately $393,633.76. The disclosure for this sale can be found here. Insiders have sold 401,360 shares of company stock valued at $15,759,096 in the last three months. 11.10% of the stock is currently owned by company insiders.
WARNING: “Acadia Healthcare (NASDAQ:ACHC) Stake Lowered by HPM Partners LLC” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/hpm-partners-llc-has-528000-position-in-acadia-healthcare-company-inc-achc.html.
Acadia Healthcare Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.